Literature DB >> 8288673

Transplacental carcinogenicity of low doses of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone administered subcutaneously or intratracheally to hamsters.

H M Schüller1, R Jorquera, X Lu, A Riechert, A Castonguay.   

Abstract

Our previous studies have demonstrated that doses of 300-50 mg/kg 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) injected subcutaneously into pregnant hamsters cause a 44% incidence of respiratory-tract tumors in the offspring. In this study, we have extended the assay of the carcinogenic potency of NNK to doses ranging from 50 mg to 0.05 mg/kg body weight and to a second route of administration, intratracheal instillation, which is more relevant to inhalation of tobacco smoke by pregnant women. Among the offspring whose mothers had been injected subcutaneously with NNK (20-1 mg/kg), the total tumor incidence (57.2%-16.7%) decreased with decreasing dose levels. After intratracheal instillation of 50-0.05 mg/kg NNK the overall incidence varied from 28.6% to 50% but no dose response was observed. The main target organs were the adrenal glands (Phaechromocytomas) and nasal cavities (adenocarcinomas of the olfactory region). A low incidence of ductular adenomas of the pancreas was observed with low doses of NNK instilled intratracheally. These results demonstrate that NNK, at doses that are comparable to the cumulative exposure during a 9-month period in women, is a potent transplacental carcinogen in hamsters.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8288673     DOI: 10.1007/BF01372556

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  8 in total

1.  Placental transfer of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone instilled intratracheally in Syrian golden hamsters.

Authors:  R Jorquera; A Castonguay; H M Schuller
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

Review 2.  The relevance of tobacco-specific nitrosamines to human cancer.

Authors:  S S Hecht; D Hoffmann
Journal:  Cancer Surv       Date:  1989

3.  Evaluation of the transplacental tumorigenicity of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice.

Authors:  L M Anderson; S S Hecht; D E Dixon; L F Dove; R M Kovatch; S Amin; D Hoffmann; J M Rice
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

4.  Induction of exocrine pancreatic, bile duct, and thyroid gland tumors in offspring of Syrian hamsters treated with N-nitrosobis(2-oxopropyl)amine during pregnancy.

Authors:  P M Pour
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

5.  Transplacental effects of diethylnitrosamine in Syrian hamsters as related to different days of administration during pregnancy.

Authors:  U Mohr; H Reznik-Schüller; G Reznik; J Hilfrich
Journal:  J Natl Cancer Inst       Date:  1975-09       Impact factor: 13.506

6.  The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is an active transplacental carcinogen in Syrian golden hamsters.

Authors:  E Correa; P A Joshi; A Castonguay; H M Schüller
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

7.  Cancer risk in adulthood from early life exposure to parents' smoking.

Authors:  D P Sandler; R B Everson; A J Wilcox; J P Browder
Journal:  Am J Public Health       Date:  1985-05       Impact factor: 9.308

8.  Maternal smoking during pregnancy and risk of childhood cancer.

Authors:  M Stjernfeldt; K Berglund; J Lindsten; J Ludvigsson
Journal:  Lancet       Date:  1986-06-14       Impact factor: 79.321

  8 in total
  8 in total

Review 1.  [Effects of alcohol and smoking in pregnancy].

Authors:  V Thäle; A Schlitt
Journal:  Internist (Berl)       Date:  2011-10       Impact factor: 0.743

2.  Carcinogenicity and DNA adduct formation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in F-344 rats.

Authors:  Silvia Balbo; Charles S Johnson; Ramesh C Kovi; Sandra A James-Yi; M Gerard O'Sullivan; Mingyao Wang; Chap T Le; Samir S Khariwala; Pramod Upadhyaya; Stephen S Hecht
Journal:  Carcinogenesis       Date:  2014-09-30       Impact factor: 4.944

Review 3.  The pathobiological impact of cigarette smoke on pancreatic cancer development (review).

Authors:  Uwe A Wittel; Navneet Momi; Gabriel Seifert; Thorsten Wiech; Ulrich T Hopt; Surinder K Batra
Journal:  Int J Oncol       Date:  2012-03-23       Impact factor: 5.650

4.  Metastasis to the F344 Rat Pancreas from Lung Cancer Induced by 4-(Methylnitrosamino)- 1-(3-pyridyl)-1-butanone and Enantiomers of Its Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)- 1-butanol, Constituents of Tobacco Products.

Authors:  Ramesh C Kovi; Charles S Johnson; Silvia Balbo; Stephen S Hecht; M Gerard O'Sullivan
Journal:  Toxicol Pathol       Date:  2018-02-01       Impact factor: 1.902

Review 5.  Long-term consequences of fetal and neonatal nicotine exposure: a critical review.

Authors:  Jennifer E Bruin; Hertzel C Gerstein; Alison C Holloway
Journal:  Toxicol Sci       Date:  2010-04-02       Impact factor: 4.849

6.  Urine 4-(methylnitrosamino)-1-(3) pyridyl-1-butanol and cotinine in Alaska native postpartum women and neonates comparing smokers and smokeless tobacco users.

Authors:  Neal L Benowitz; Christie A Flanagan; Timothy K Thomas; Kathryn R Koller; Abbie W Wolfe; Caroline C Renner; Christine Hughes; Paul A Decker; Dorothy K Hatsukami; Neil J Murphy; Christi Patten
Journal:  Int J Circumpolar Health       Date:  2018-12       Impact factor: 1.228

7.  Parental smoking and childhood cancer: results from the United Kingdom Childhood Cancer Study.

Authors:  D Pang; R McNally; J M Birch
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

8.  Induction of lung lesions in Wistar rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by aspirin and phenethyl isothiocyanate.

Authors:  Bo Ye; Yu-Xia Zhang; Fei Yang; Hong-Lei Chen; Dong Xia; Ming-Qiu Liu; Bai-Tang Lai
Journal:  BMC Cancer       Date:  2007-05-29       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.